Cost-offset analysis: bimatoprost versus other XXXX analogues in open-angle glaucoma.

@entity1 @entity2789 @entity6987 @entity725 @entity726 @entity3009
OBJECTIVES: To develop a cost-offset model from a US payer perspective comparing @entity2789 and costs among @entity725 ( @entity725 ) @entity1 using bimatoprost, latanoprost, or travoprost. STUDY DESIGN: Cost-offset model. METHODS: A Markov cohort model was used to estimate @entity2789 for @entity725 @entity1 over 7 years. The model assumed bimatoprost-treated @entity1 had lower resulting intraocular pressure (IOP) (by 1 mm Hg) for all presenting IOP categories than latanoprost- or travoprost-treated @entity1 . @entity1 with lower IOP were assumed to have lower probability of progression. Those that progressed were assumed to do so at a rate of -0.6 dB per year. Direct costs associated with mean deviation score categories were applied to each treatment cohort to calculate the expected 7-year costs of treating @entity1 with each @entity3009 analogue ( @entity6987 ). Literature was used to support assumptions. A budget impact analysis was conducted where all travoprost @entity1 switched to generic latanoprost and where all bimatoprost @entity1 switched to generic latanoprost. The base case market share was 22% bimatoprost, 23% travoprost, and 55% latanoprost. RESULTS: Model results demonstrate that for a managed care plan with 9500 @entity6987 -treated @entity726 @entity1 , exclusive bimatoprost use would prevent progression in 136 additional individuals compared with exclusive travoprost or latanoprost treatment. Model results demonstrate that greater IOP reduction from bimatoprost is associated with increased cost savings compared with latanoprost or travoprost treatments. CONCLUSIONS: Model results demonstrate that greater IOP reduction from bimatoprost could reduce managed care spending.
